ABBV-706 (SEZ6 ADC)

May 21, 2026 — AbbVie announced it will present multiple oral and poster presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, highlighting progress across its next-generation oncology pipeline, including Topoisomerase I inhibitor (Top1i) antibody-drug conjugates (ADCs) and T‑cell engagers (TCEs).

Key data include: in a Phase 1 first-in-human study (NCT06318273), ABBV‑969 (bispecific PSMA/STEAP1 ADC) showed a confirmed objective response rate (ORR) of 45% (29 RECIST-evaluable) in heavily pretreated metastatic castration-resistant prostate cancer, with PSA50 in 67% and PSA90 in 28%, and a manageable safety profile. In small cell lung cancer, Phase 1 monotherapy data (NCT05599984) for ABBV‑706 (SEZ6-directed ADC) reported an ORR of 82% at the recommended Phase 3 dose (1.8 mg/kg) as second-line therapy (n=17), supporting continued evaluation. In relapsed/refractory multiple myeloma, Phase 1b data for etentamig (BCMA×CD3 TCE; NCT05650632) showed ORR 64% among patients treated after prior BCMA CAR‑T (n=11), median duration of response 13 months, MRD negativity 67% (2/3 evaluable), and only grade 1–2 cytokine release syndrome despite no step-up dosing.

AbbVie also reported Phase 1 basket evidence of antitumor activity for telisotuzumab adizutecan (Temab‑A/ABBV‑400; c‑Met ADC) in platinum-resistant ovarian cancer and head and neck squamous cell carcinoma, supporting broader development.